Clinical Trial

CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
A Phase 2 study to evaluate the safety and efficacy of TORL-1-23 in patients with advanced ovarian cancer.
Protocol Amendment History 16 amendments
This ClinicalTrials.gov record has been amended 16 times since 2024-11-13; most recent amendment 2025-12-19.
Status change: Not Yet Recruiting → Recruiting 2024-12-02
Trial Details
NCT Number NCT06690775
Lead Sponsor TORL Biotherapeutics, LLC
Collaborators: European Network of Gynaecological Oncological Trial Groups (ENGOT)
Conditions Epithelial Ovarian Cancer, Primary Peritoneal, Fallopian Tube Cancer, Endometrioid Ovarian Cancer
Enrollment 230 participants
Start Date 2024-11-20
Primary Completion 2027-10 (estimated)
Study Completion 2027-12 (estimated)
Updated on ClinicalTrials.gov 2025-12-23